reading others comments on trading and likely accumulation over the past months, together with the less than encouraging half yearly statement by management, is it likely that DS will make an offer for BTA, given the appraent success of Inavir and the recent development by DS for a manufacturing facility in the US ?
Which when translated into Japanese (politely) - "how can we work with this Aussie company they do not have the ability or track record to advance Inavir"
DS to the best of my research have not made any recent profound statements on ROW for Inavir, I think they maybe a sleeper waiting to pounce
BTA Price at posting:
$1.06 Sentiment: Buy Disclosure: Held
